Background: In 2014, the COIN-B clinical trial demonstrated that intermittent cetuximab (IC) was a safe alternative to continuous cetuximab (CC), with less cytotoxic chemotherapy, in first-line treatment for KRAS wild-type metastatic colorectal cancer (mCRC). Cetuximab has been available for this indication in England since 2015, but treatment breaks beyond 6 weeks were prohibited, despite real-world evidence that therapy de-escalation maintains equivalent disease control, but with superior Quality-of-Life (QoL). We performed health economic analyses of IC versus CC and used this evidence to help underpin policy change and guide clinical practice through reduction in unnecessary treatment for mCRC patients.

Methods: Employing cost-minimization analysis, we conducted partitioned survival modelling (PSM) and Markov Chain Monte-Carlo (MCMC) simulation to determine costs and quality-adjusted-life-years for IC versus CC.

Results: IC reduced costs by £ 35,763 (PSM; p < 0.001) or £ 30,189 (MCMC) per patient annually, while preserving treatment efficacy and enhancing QoL. Extrapolating to all mCRC patients eligible for cetuximab therapy would have generated cost savings of ~£ 1.2 billion over this cohort's lifetime. These data helped underpin a request to NHS England to remove treatment break restrictions in first-line mCRC therapy, which has been adopted as an interim treatment option policy in colorectal cancer during the Covid-19 pandemic.

Conclusions: Our results highlight substantial cost savings achievable by treatment de-escalation, while also reinforcing the importance of therapy breaks to potentially increase tumour responsiveness and reduce treatment toxicity. Our study also highlights how health economic evidence can influence health policy, championing reduced treatment intensity approaches without compromising patient outcomes, which is of particular relevance when addressing the reduced capacity and treatment backlogs experienced during the pandemic.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcpo.2022.100342DOI Listing

Publication Analysis

Top Keywords

continuous cetuximab
8
kras wild-type
8
metastatic colorectal
8
colorectal cancer
8
spend achieve
4
achieve economic
4
economic analysis
4
analysis intermittent
4
intermittent versus
4
versus continuous
4

Similar Publications

Targeting FABP4/UCP2 axis to overcome cetuximab resistance in obesity-driven CRC with drug-tolerant persister cells.

Transl Oncol

January 2025

Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan; Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan; Department of Radiology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan. Electronic address:

Colorectal cancer (CRC) is closely linked to obesity, a condition that significantly impacts tumor progression and therapeutic resistance. Although cetuximab, an EGFR-targeting monoclonal antibody, is a cornerstone in metastatic CRC treatment, resistance often emerges, leading to poor outcomes. This study investigated the role of drug-tolerant persister (DTP) cells and their metabolic interactions within the tumor microenvironment (TME) in cetuximab resistance.

View Article and Find Full Text PDF

Background: Encorafenib plus cetuximab (EC) is the standard of care for pre-treated mutated metastatic colorectal cancer (mCRC). Depth of response (DpR) and early tumour shrinkage (ETS) previously showed a strong correlation with survival outcomes of first-line chemotherapy ± biological agents.

Objectives: We aimed to assess potential predictors of primary resistance to EC ± binimetinib (B) and relationships of DpR/ETS with survival outcomes and clinical characteristics.

View Article and Find Full Text PDF

Epidermal growth factor receptor (EGFR) inhibitors have largely been used for head and neck cancers, non-small cell lung cancers, and colorectal cancers (CRC). Reports of interstitial pneumonitis with EGFR inhibitors like gefitinib and erlotinib are present in the literature, but pulmonary toxicity with cetuximab has rarely been reported. We present a case of a 78-year-old male with metastatic CRC involving the brain and lungs who presented with severe pneumonitis, a month after treatment with cetuximab.

View Article and Find Full Text PDF

Purpose: This phase Ib trial evaluated fibroblast activation protein-α-targeted IL2 variant (FAP-IL2v), a novel immunocytokine engineered to minimize CD25-mediated toxicities, in combination with cetuximab, in patients with recurrent, unresectable, or metastatic head and neck squamous cell carcinoma (HNSCC).

Patients And Methods: Patients received FAP-IL2v either on a continuous weekly (QW) schedule or QW for 4 weeks and then every 2 weeks (Q2W). Cetuximab was dosed at QW or Q2W schedules.

View Article and Find Full Text PDF

A Review of Immunotherapy for Head and Neck Cancer.

J Dent Res

November 2024

Oral Medicine, Oral Oncology and Dentistry, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, USA.

Article Synopsis
  • The introduction of immune checkpoint inhibitors, like pembrolizumab, has improved treatment outcomes for head and neck squamous cell carcinoma (HNSCC), moving beyond traditional chemotherapy options.
  • Combination therapies that include immunotherapy are being explored in clinical trials, and personalization based on tumor biomarkers is becoming crucial for optimizing treatment plans.
  • There's a need for further clinical research and standardized guidelines, particularly concerning dental care and management of oral side effects, to enhance the effectiveness of immunotherapy in HNSCC patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!